Search

Your search keyword '"Halaban, Ruth"' showing total 521 results
Start Over Author "Halaban, Ruth"
521 results on '"Halaban, Ruth"'

1. Interferon-stimulated neutrophils as a predictor of immunotherapy response

Author

Benguigui, Madeleine, Cooper, Tim J., Kalkar, Prajakta, Schif-Zuck, Sagie, Halaban, Ruth, Bacchiocchi, Antonella, Kamer, Iris, Deo, Abhilash, Manobla, Bar, Menachem, Rotem, Haj-Shomaly, Jozafina, Vorontsova, Avital, Raviv, Ziv, Buxbaum, Chen, Christopoulos, Petros, Bar, Jair, Lotem, Michal, Sznol, Mario, Ariel, Amiram, Shen-Orr, Shai S., and Shaked, Yuval

Published
2024
Full Text
View/download PDF

4. Clonal determinants of organotropism and survival in metastatic uveal melanoma

Author

Jones, Bailey SCL, primary, Demkowicz, Patrick C, additional, Matesva, Mitchelle, additional, Lim, Renelle Pointdujour, additional, Sinard, John H, additional, Bacchiocchi, Antonietta, additional, Halaban, Ruth, additional, Bosenberg, Marcus, additional, Sznol, Mario, additional, Kluger, Harriet M, additional, and Bakhoum, Mathieu F, additional

Published
2024
Full Text
View/download PDF

6. Circulating Tumor Reactive KIR+CD8+ T cells Suppress Anti-Tumor Immunity in Patients with Melanoma

Author

Hafler, David, primary, Lu, Benjamin, additional, Lucca, Liliana, additional, Lewis, Wesley, additional, Wang, Jiping, additional, Nogeuira, Catarina, additional, Heer, Sebastian, additional, Axisa, Pierre-Paul, additional, Buitrago-Pocasangre, Nicholas, additional, Pham, Giang, additional, Kojima, Mina, additional, Wei, Wei, additional, Aizenbud, Lilach, additional, Bacchiocchi, Antonietta, additional, Zhang, Lin, additional, Walewski, Joseph, additional, Chiang, Veronica, additional, Olino, Kelly, additional, Clune, James, additional, Halaban, Ruth, additional, Kluger, Yuval, additional, Coyle, Anthony, additional, Kisielow, Jan, additional, Obermair, Franz-Josef, additional, and Kluger, Harriet, additional

Published
2024
Full Text
View/download PDF

7. Author Correction: Integrative molecular and clinical profiling of acral melanoma links focal amplification of 22q11.21 to metastasis

Author

Farshidfar, Farshad, Rhrissorrakrai, Kahn, Levovitz, Chaya, Peng, Cong, Knight, James, Bacchiocchi, Antonella, Su, Juan, Yin, Mingzhu, Sznol, Mario, Ariyan, Stephan, Clune, James, Olino, Kelly, Parida, Laxmi, Nikolaus, Joerg, Zhang, Meiling, Zhao, Shuang, Wang, Yan, Huang, Gang, Wan, Miaojian, Li, Xianan, Cao, Jian, Yan, Qin, Chen, Xiang, Newman, Aaron M., and Halaban, Ruth

Published
2022
Full Text
View/download PDF

8. Integrative molecular and clinical profiling of acral melanoma links focal amplification of 22q11.21 to metastasis

Author

Farshidfar, Farshad, Rhrissorrakrai, Kahn, Levovitz, Chaya, Peng, Cong, Knight, James, Bacchiocchi, Antonella, Su, Juan, Yin, Mingzhu, Sznol, Mario, Ariyan, Stephan, Clune, James, Olino, Kelly, Parida, Laxmi, Nikolaus, Joerg, Zhang, Meiling, Zhao, Shuang, Wang, Yan, Huang, Gang, Wan, Miaojian, Li, Xianan, Cao, Jian, Yan, Qin, Chen, Xiang, Newman, Aaron M., and Halaban, Ruth

Published
2022
Full Text
View/download PDF

9. T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma

Author

Lozano, Alexander X., Chaudhuri, Aadel A., Nene, Aishwarya, Bacchiocchi, Antonietta, Earland, Noah, Vesely, Matthew D., Usmani, Abul, Turner, Brandon E., Steen, Chloé B., Luca, Bogdan A., Badri, Ti, Gulati, Gunsagar S., Vahid, Milad R., Khameneh, Farnaz, Harris, Peter K., Chen, David Y., Dhodapkar, Kavita, Sznol, Mario, Halaban, Ruth, and Newman, Aaron M.

Published
2022
Full Text
View/download PDF

10. Ultra-sensitive molecular residual disease detection through whole genome sequencing with single-read error correction

Author

Li, Xinxing, primary, Liu, Tao, additional, Bacchiocchi, Antonella, additional, Li, Mengxing, additional, Cheng, Wen, additional, Wittkop, Tobias, additional, Mendez, Fernando, additional, Wang, Yingyu, additional, Tang, Paul, additional, Yao, Qianqian, additional, Bosenberg, Marcus W., additional, Sznol, Mario, additional, Yan, Qin, additional, Faham, Malek, additional, Weng, Li, additional, Halaban, Ruth, additional, Jin, Hai, additional, and Hu, Zhiqian, additional

Published
2024
Full Text
View/download PDF

11. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013

Author

Ascierto, Paolo A, Grimaldi, Antonio M, Anderson, Ana Carrizosa, Bifulco, Carlo, Cochran, Alistair, Garbe, Claus, Eggermont, Alexander M, Faries, Mark, Ferrone, Soldano, Gershenwald, Jeffrey E, Gajewski, Thomas F, Halaban, Ruth, Hodi, F Stephen, Kefford, Richard, Kirkwood, John M, Larkin, James, Leachman, Sancy, Maio, Michele, Marais, Richard, Masucci, Giuseppe, Melero, Ignacio, Palmieri, Giuseppe, Puzanov, Igor, Ribas, Antoni, Saenger, Yvonne, Schilling, Bastian, Seliger, Barbara, Stroncek, David, Sullivan, Ryan, Testori, Alessandro, Wang, Ena, Ciliberto, Gennaro, Mozzillo, Nicola, Marincola, Francesco M, and Thurin, Magdalena

Subjects
Cancer, Vaccine Related, Immunization, Biotechnology, Detection, screening and diagnosis, Development of treatments and therapeutic interventions, 5.1 Pharmaceuticals, 4.1 Discovery and preclinical testing of markers and technologies, Good Health and Well Being, Humans, Immunotherapy, Italy, Melanoma, Medical and Health Sciences, Immunology
Abstract

The fourth "Melanoma Bridge Meeting" took place in Naples, December 5 to 8th, 2013. The four topics discussed at this meeting were: Diagnosis and New Procedures, Molecular Advances and Combination Therapies, News in Immunotherapy, and Tumor Microenvironment and Biomarkers.

Published
2014

12. CD4 T cells and toxicity from immune checkpoint blockade

Author

Earland, Noah, primary, Zhang, Wubing, additional, Usmani, Abul, additional, Nene, Aishwarya, additional, Bacchiocchi, Antonella, additional, Chen, David Y., additional, Sznol, Mario, additional, Halaban, Ruth, additional, Chaudhuri, Aadel A., additional, and Newman, Aaron M., additional

Published
2023
Full Text
View/download PDF

13. Future Perspectives in melanoma research:Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7th 2010".

Author

Ascierto, Paolo A, De Maio, Eleonora, Bertuzzi, Stefano, Palmieri, Giuseppe, Halaban, Ruth, Hendrix, Mary, Kashani-sabet, Mohamed, Ferrone, Soldano, Wang, Ena, Cochran, Alistair, Rivoltini, Licia, Lee, Peter P, Fox, Bernard A, Kirkwood, John M, Ullmann, Claudio, Lehmann, Frederic F, Sznol, Mario, Schwartzentruber, Douglas J, Maio, Michele, Flaherty, Keith, Galon, Jerome, Ribas, Antoni, Yang, James, Stroncek, David F, Mozzillo, Nicola, and Marincola, Franco M

Abstract

Abstract Progress in understanding the molecular basis of melanoma has made possible the identification of molecular targets with important implications in clinical practice. In fact, new therapeutic approaches are emerging from basic science and it will be important to implement their rapid translation into clinical practice by active clinical investigation. The first meeting of Melanoma Research: a bridge Naples-USA, organized by Paolo A. Ascierto (INT, Naples, Italy) and Francesco Marincola (NIH, Bethesda, USA) took place in Naples, on 6-7 December 2010. This international congress gathered more than 30 international and Italian faculty members and was focused on recent advances in melanoma molecular biology, immunology and therapy, and created an interactive discussion across Institutions belonging to Government, Academy and Pharmaceutical Industry, in order to stimulate new approaches in basic, translational and clinical research. Four topics of discussion were identified: New pathways in Melanoma, Biomarkers, Clinical Trials and New Molecules and Strategies.

Published
2011

14. Abstract 6670: Association between circulating CD4 memory T cell levels and severe immune-related adverse events in melanoma patients treated with immune checkpoint blockade

Author

Usmani, Abul, primary, Earland, Noah, additional, Zhang, Wubing, additional, Harris, Peter K., additional, Bacchiocchi, Antonietta, additional, Nene, Aishwarya, additional, Chen, David Y., additional, Sznol, Mario, additional, Halaban, Ruth, additional, Newman, Aaron M., additional, and Chaudhuri, Aadel A., additional

Published
2023
Full Text
View/download PDF

15. Supplementary Figure 6 from Preexisting MEK1 Exon 3 Mutations in V600E/KBRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors

Author

Shi, Hubing, primary, Moriceau, Gatien, primary, Kong, Xiangju, primary, Koya, Richard C., primary, Nazarian, Ramin, primary, Pupo, Gulietta M., primary, Bacchiocchi, Antonella, primary, Dahlman, Kimberly B., primary, Chmielowski, Bartosz, primary, Sosman, Jeffrey A., primary, Halaban, Ruth, primary, Kefford, Richard F., primary, Long, Georgina V., primary, Ribas, Antoni, primary, and Lo, Roger S., primary

Published
2023
Full Text
View/download PDF

16. Supplementary Figure 4 from Preexisting MEK1 Exon 3 Mutations in V600E/KBRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors

Author

Shi, Hubing, primary, Moriceau, Gatien, primary, Kong, Xiangju, primary, Koya, Richard C., primary, Nazarian, Ramin, primary, Pupo, Gulietta M., primary, Bacchiocchi, Antonella, primary, Dahlman, Kimberly B., primary, Chmielowski, Bartosz, primary, Sosman, Jeffrey A., primary, Halaban, Ruth, primary, Kefford, Richard F., primary, Long, Georgina V., primary, Ribas, Antoni, primary, and Lo, Roger S., primary

Published
2023
Full Text
View/download PDF

18. Supplementary Figure 3 from Preexisting MEK1 Exon 3 Mutations in V600E/KBRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors

Author

Shi, Hubing, primary, Moriceau, Gatien, primary, Kong, Xiangju, primary, Koya, Richard C., primary, Nazarian, Ramin, primary, Pupo, Gulietta M., primary, Bacchiocchi, Antonella, primary, Dahlman, Kimberly B., primary, Chmielowski, Bartosz, primary, Sosman, Jeffrey A., primary, Halaban, Ruth, primary, Kefford, Richard F., primary, Long, Georgina V., primary, Ribas, Antoni, primary, and Lo, Roger S., primary

Published
2023
Full Text
View/download PDF

19. Supplementary Figure 1 from Preexisting MEK1 Exon 3 Mutations in V600E/KBRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors

Author

Shi, Hubing, primary, Moriceau, Gatien, primary, Kong, Xiangju, primary, Koya, Richard C., primary, Nazarian, Ramin, primary, Pupo, Gulietta M., primary, Bacchiocchi, Antonella, primary, Dahlman, Kimberly B., primary, Chmielowski, Bartosz, primary, Sosman, Jeffrey A., primary, Halaban, Ruth, primary, Kefford, Richard F., primary, Long, Georgina V., primary, Ribas, Antoni, primary, and Lo, Roger S., primary

Published
2023
Full Text
View/download PDF

20. Supplementary Figure 2 from Preexisting MEK1 Exon 3 Mutations in V600E/KBRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors

Author

Shi, Hubing, primary, Moriceau, Gatien, primary, Kong, Xiangju, primary, Koya, Richard C., primary, Nazarian, Ramin, primary, Pupo, Gulietta M., primary, Bacchiocchi, Antonella, primary, Dahlman, Kimberly B., primary, Chmielowski, Bartosz, primary, Sosman, Jeffrey A., primary, Halaban, Ruth, primary, Kefford, Richard F., primary, Long, Georgina V., primary, Ribas, Antoni, primary, and Lo, Roger S., primary

Published
2023
Full Text
View/download PDF

23. Data from Preexisting MEK1 Exon 3 Mutations in V600E/KBRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors

Author

Shi, Hubing, primary, Moriceau, Gatien, primary, Kong, Xiangju, primary, Koya, Richard C., primary, Nazarian, Ramin, primary, Pupo, Gulietta M., primary, Bacchiocchi, Antonella, primary, Dahlman, Kimberly B., primary, Chmielowski, Bartosz, primary, Sosman, Jeffrey A., primary, Halaban, Ruth, primary, Kefford, Richard F., primary, Long, Georgina V., primary, Ribas, Antoni, primary, and Lo, Roger S., primary

Published
2023
Full Text
View/download PDF

24. Data from A Serum Protein Signature Associated with Outcome after Anti–PD-1 Therapy in Metastatic Melanoma

Author

Weber, Jeffrey S., primary, Sznol, Mario, primary, Sullivan, Ryan J., primary, Blackmon, Shauna, primary, Boland, Genevieve, primary, Kluger, Harriet M., primary, Halaban, Ruth, primary, Bacchiocchi, Antonietta, primary, Ascierto, Paolo A., primary, Capone, Mariaelena, primary, Oliveira, Carlos, primary, Meyer, Krista, primary, Grigorieva, Julia, primary, Asmellash, Senait G., primary, Roder, Joanna, primary, and Roder, Heinrich, primary

Published
2023
Full Text
View/download PDF

27. Supplemental Material, Supplementary Figures 1 and 2, Supplemental Tables 1 - 8 from A Serum Protein Signature Associated with Outcome after Anti–PD-1 Therapy in Metastatic Melanoma

Author

Weber, Jeffrey S., primary, Sznol, Mario, primary, Sullivan, Ryan J., primary, Blackmon, Shauna, primary, Boland, Genevieve, primary, Kluger, Harriet M., primary, Halaban, Ruth, primary, Bacchiocchi, Antonietta, primary, Ascierto, Paolo A., primary, Capone, Mariaelena, primary, Oliveira, Carlos, primary, Meyer, Krista, primary, Grigorieva, Julia, primary, Asmellash, Senait G., primary, Roder, Joanna, primary, and Roder, Heinrich, primary

Published
2023
Full Text
View/download PDF

28. Supplementary Figure 5 from Preexisting MEK1 Exon 3 Mutations in V600E/KBRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors

Author

Shi, Hubing, primary, Moriceau, Gatien, primary, Kong, Xiangju, primary, Koya, Richard C., primary, Nazarian, Ramin, primary, Pupo, Gulietta M., primary, Bacchiocchi, Antonella, primary, Dahlman, Kimberly B., primary, Chmielowski, Bartosz, primary, Sosman, Jeffrey A., primary, Halaban, Ruth, primary, Kefford, Richard F., primary, Long, Georgina V., primary, Ribas, Antoni, primary, and Lo, Roger S., primary

Published
2023
Full Text
View/download PDF

30. Supplementary Figure 7 from Preexisting MEK1 Exon 3 Mutations in V600E/KBRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors

Author

Shi, Hubing, primary, Moriceau, Gatien, primary, Kong, Xiangju, primary, Koya, Richard C., primary, Nazarian, Ramin, primary, Pupo, Gulietta M., primary, Bacchiocchi, Antonella, primary, Dahlman, Kimberly B., primary, Chmielowski, Bartosz, primary, Sosman, Jeffrey A., primary, Halaban, Ruth, primary, Kefford, Richard F., primary, Long, Georgina V., primary, Ribas, Antoni, primary, and Lo, Roger S., primary

Published
2023
Full Text
View/download PDF

37. Supplementary Table 3 from Expression Profiling Reveals Novel Pathways in the Transformation of Melanocytes to Melanomas

Author

Hoek, Keith, primary, Rimm, David L., primary, Williams, Kenneth R., primary, Zhao, Hongyu, primary, Ariyan, Stephan, primary, Lin, Aiping, primary, Kluger, Harriet M., primary, Berger, Aaron J., primary, Cheng, Elaine, primary, Trombetta, E. Sergio, primary, Wu, Terence, primary, Niinobe, Michio, primary, Yoshikawa, Kazuaki, primary, Hannigan, Gregory E., primary, and Halaban, Ruth, primary

Published
2023
Full Text
View/download PDF

38. Supplementary Table S2 from PDK1 and SGK3 Contribute to the Growth of BRAF-Mutant Melanomas and Are Potential Therapeutic Targets

Author

Scortegagna, Marzia, primary, Lau, Eric, primary, Zhang, Tongwu, primary, Feng, Yongmei, primary, Sereduk, Chris, primary, Yin, Hongwei, primary, De, Surya K., primary, Meeth, Katrina, primary, Platt, James T., primary, Langdon, Casey G., primary, Halaban, Ruth, primary, Pellecchia, Maurizio, primary, Davies, Michael A., primary, Brown, Kevin, primary, Stern, David F., primary, Bosenberg, Marcus, primary, and Ronai, Ze'ev A., primary

Published
2023
Full Text
View/download PDF

39. Data from PDK1 and SGK3 Contribute to the Growth of BRAF-Mutant Melanomas and Are Potential Therapeutic Targets

Author

Scortegagna, Marzia, primary, Lau, Eric, primary, Zhang, Tongwu, primary, Feng, Yongmei, primary, Sereduk, Chris, primary, Yin, Hongwei, primary, De, Surya K., primary, Meeth, Katrina, primary, Platt, James T., primary, Langdon, Casey G., primary, Halaban, Ruth, primary, Pellecchia, Maurizio, primary, Davies, Michael A., primary, Brown, Kevin, primary, Stern, David F., primary, Bosenberg, Marcus, primary, and Ronai, Ze'ev A., primary

Published
2023
Full Text
View/download PDF

40. Supplementary Table 1 from Expression Profiling Reveals Novel Pathways in the Transformation of Melanocytes to Melanomas

Author

Hoek, Keith, primary, Rimm, David L., primary, Williams, Kenneth R., primary, Zhao, Hongyu, primary, Ariyan, Stephan, primary, Lin, Aiping, primary, Kluger, Harriet M., primary, Berger, Aaron J., primary, Cheng, Elaine, primary, Trombetta, E. Sergio, primary, Wu, Terence, primary, Niinobe, Michio, primary, Yoshikawa, Kazuaki, primary, Hannigan, Gregory E., primary, and Halaban, Ruth, primary

Published
2023
Full Text
View/download PDF

41. Supplementary Figures S1-S6 from PDK1 and SGK3 Contribute to the Growth of BRAF-Mutant Melanomas and Are Potential Therapeutic Targets

Author

Scortegagna, Marzia, primary, Lau, Eric, primary, Zhang, Tongwu, primary, Feng, Yongmei, primary, Sereduk, Chris, primary, Yin, Hongwei, primary, De, Surya K., primary, Meeth, Katrina, primary, Platt, James T., primary, Langdon, Casey G., primary, Halaban, Ruth, primary, Pellecchia, Maurizio, primary, Davies, Michael A., primary, Brown, Kevin, primary, Stern, David F., primary, Bosenberg, Marcus, primary, and Ronai, Ze'ev A., primary

Published
2023
Full Text
View/download PDF

42. Supplementary Table 2 from Expression Profiling Reveals Novel Pathways in the Transformation of Melanocytes to Melanomas

Author

Hoek, Keith, primary, Rimm, David L., primary, Williams, Kenneth R., primary, Zhao, Hongyu, primary, Ariyan, Stephan, primary, Lin, Aiping, primary, Kluger, Harriet M., primary, Berger, Aaron J., primary, Cheng, Elaine, primary, Trombetta, E. Sergio, primary, Wu, Terence, primary, Niinobe, Michio, primary, Yoshikawa, Kazuaki, primary, Hannigan, Gregory E., primary, and Halaban, Ruth, primary

Published
2023
Full Text
View/download PDF

43. Supplementary Table and Figure Legends from PDK1 and SGK3 Contribute to the Growth of BRAF-Mutant Melanomas and Are Potential Therapeutic Targets

Author

Scortegagna, Marzia, primary, Lau, Eric, primary, Zhang, Tongwu, primary, Feng, Yongmei, primary, Sereduk, Chris, primary, Yin, Hongwei, primary, De, Surya K., primary, Meeth, Katrina, primary, Platt, James T., primary, Langdon, Casey G., primary, Halaban, Ruth, primary, Pellecchia, Maurizio, primary, Davies, Michael A., primary, Brown, Kevin, primary, Stern, David F., primary, Bosenberg, Marcus, primary, and Ronai, Ze'ev A., primary

Published
2023
Full Text
View/download PDF

44. Integrative analysis of epigenetic modulation in melanoma cell response to decitabine: clinical implications.

Author

Halaban, Ruth, Krauthammer, Michael, Pelizzola, Mattia, Cheng, Elaine, Kovacs, Daniela, Sznol, Mario, Ariyan, Stephan, Narayan, Deepak, Bacchiocchi, Antonella, Molinaro, Annette, Kluger, Yuval, Deng, Min, Tran, Nam, Zhang, Wengeng, Picardo, Mauro, and Enghild, Jan J

Subjects
Cell Line, Tumor, Humans, Melanoma, DNA Damage, Azacitidine, Gene Expression Profiling, Computational Biology, Apoptosis, Cell Proliferation, Epigenesis, Genetic, Gene Expression Regulation, Neoplastic, Drug Resistance, Neoplasm, Biomarkers, Tumor, Decitabine, Biomarkers, Tumor, Cell Line, Drug Resistance, Neoplasm, Epigenesis, Genetic, Gene Expression Regulation, Neoplastic, General Science & Technology
Abstract

Decitabine, an epigenetic modifier that reactivates genes otherwise suppressed by DNA promoter methylation, is effective for some, but not all cancer patients, especially those with solid tumors. It is commonly recognized that to overcome resistance and improve outcome, treatment should be guided by tumor biology, which includes genotype, epigenotype, and gene expression profile. We therefore took an integrative approach to better understand melanoma cell response to clinically relevant dose of decitabine and identify complementary targets for combined therapy. We employed eight different melanoma cell strains, determined their growth, apoptotic and DNA damage responses to increasing doses of decitabine, and chose a low, clinically relevant drug dose to perform whole-genome differential gene expression, bioinformatic analysis, and protein validation studies. The data ruled out the DNA damage response, demonstrated the involvement of p21(Cip1) in a p53-independent manner, identified the TGFbeta pathway genes CLU and TGFBI as markers of sensitivity to decitabine and revealed an effect on histone modification as part of decitabine-induced gene expression. Mutation analysis and knockdown by siRNA implicated activated beta-catenin/MITF, but not BRAF, NRAS or PTEN mutations as a source for resistance. The importance of protein stability predicted from the results was validated by the synergistic effect of Bortezomib, a proteasome inhibitor, in enhancing the growth arrest of decitabine in otherwise resistant melanoma cells. Our integrative analysis show that improved therapy can be achieved by comprehensive analysis of cancer cells, identified biomarkers for patient's selection and monitoring response, as well as targets for improved combination therapy.

Published
2009

48. Early B cell changes predict autoimmunity following combination immune checkpoint blockade

Author

Das, Rituparna, Bar, Noffar, Ferreira, Michelle, Newman, Aaron M., Zhang, Lin, Bailur, Jithendra Kini, Bacchiocchi, Antonella, Kluger, Harriet, Wei, Wei, Halaban, Ruth, Sznol, Mario, Dhodapkar, Madhav V., and Dhodapkar, Kavita M.

Subjects
B cells -- Health aspects, Autoimmunity -- Physiological aspects, Health care industry
Abstract

Combination checkpoint blockade (CCB) targeting inhibitory CTLA4 and PD1 receptors holds promise for cancer therapy. Immune-related adverse events (IRAEs) remain a major obstacle for the optimal application of CCB in cancer. Here, we analyzed B cell changes in patients with melanoma following treatment with either anti-CTLA4 or anti-PD1, or in combination. CCB therapy led to changes in circulating B cells that were detectable after the first cycle of therapy and characterized by a decline in circulating B cells and an increase in [CD21.sup.lo] B cells and plasmablasts. PD1 expression was higher in the [CD21.sup.lo] B cells, and B cell receptor sequencing of these cells demonstrated greater clonality and a higher frequency of clones compared with [CD21.sup.hi] cells. CCB induced proliferation in the [CD21.sup.lo] compartment, and single-cell RNA sequencing identified B cell activation in cells with genomic profiles of [CD21.sup.lo] B cells in vivo. Increased clonality of circulating B cells following CCB occurred in some patients. Treatment-induced changes in B cells preceded and correlated with both the frequency and timing of IRAEs. Patients with early B cell changes experienced higher rates of grade 3 or higher IRAEs 6 months after CCB. Thus, early changes in B cells following CCB may identify patients who are at increased risk of IRAEs, and preemptive strategies targeting B cells may reduce toxicities in these patients., Introduction Combination checkpoint blockade (CCB) therapy with anti-CTLA4 and anti-PD1 for the treatment of patients with melanoma leads to higher response rates and progression-free survival compared with treatment with either [...]

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results